BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets

Why It Matters

Even with limited early‑stage capital, these companies demonstrate that breakthrough biotech ventures can still attract significant investment, signaling confidence in next‑generation therapeutic approaches. Their progress could reshape treatment landscapes for high‑unmet‑need diseases and guide investor focus toward data‑driven, innovative models.

Key Takeaways

• Funding tight, only 15 startups secured seed/Series A
• Light Horse raised $62M and secured $1B Novartis deal
• City Therapeutics targets unmet RNAi therapeutic space
• Kardigan's Phase III ataciguat slows heart damage progression
• Stylus Medicine pursues simplified genetic cell therapies

Pulse Analysis

The biotech funding climate in 2025 grew increasingly selective, with venture capital gravitating toward later‑stage, data‑rich opportunities. Early‑stage firms therefore faced a steep hurdle to secure capital, making BioSpace’s NextGen Class of 2026 a barometer of resilience and investor confidence. By narrowing its focus to companies that announced seed or Series A rounds between October 2024 and September 2025, the list isolates the most promising innovators who managed to break through the financing squeeze.

Among the highlighted firms, Light Horse stands out for pairing a $62 million Series A raise with a headline‑making up‑to‑$1 billion collaboration with Novartis, leveraging genetic screening to accelerate oncology drug discovery. City Therapeutics, backed by ARCH Venture Partners, aims to fill gaps left by approved RNAi drugs, while Corsera Health blends AI‑enabled predictive tools with siRNA technology to develop once‑yearly cardiovascular treatments. Kardigan Therapeutics, led by former MyoKardia executives, pushes its Phase III candidate ataciguat toward reducing heart‑damage progression, and Stylus Medicine bets on streamlined genetic cell therapies amid a broader industry pullback.

The emergence of these startups suggests a strategic shift: investors are willing to fund early‑stage ventures that combine cutting‑edge science with clear partnership pathways and de‑risking mechanisms. As these companies advance toward clinical milestones, they could catalyze new therapeutic classes for rare and neglected diseases, prompting larger pharma to re‑engage with innovative pipelines. For the market, the NextGen cohort signals where capital may flow next, highlighting the importance of data‑driven platforms, strategic alliances, and differentiated pipelines in securing growth amid a constrained funding environment.